跨国公司领导人青岛峰会2025塑造罕见病的未来构建中国可持续罕见病生态系统研究报告

th第六届th跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT塑造罕见病的未来-构建中国可持续罕见病生态系统ShapingtheFutureforRareDiseases‒BuildingaSustainableRareDiseaseEcosysteminChina瑞颂制药，阿斯利康罕见病业务子公司研究成果报告th第六届跨国公司领导人青岛峰会thTHESIXTHQINGDAOMULTINATIONALSSUMMITth第六届跨国公司领导人青岛峰会thTHESIXTHQINGDAOMULTINATIONALSSUMMIT跨国公司与中国⃞链接世界合作共赢虽然单种罕见病患者数量很少，但全世界罕见病患者总数已达3亿人1。在中国，罕见病患者已达2000万人左右，每年新增病例超过20万例2，这些患者也是一国人口的重要部分。与此同时，各国越来针对罕见疾病制定的综合计划必须涵盖一系列能够满足具体需求导的是一种包容性的模式。在理论层面，患者常常被位置，但实际上，许多制度或系统的建立初衷虽然是和关注的事项，但实际操作中未能充分尊重患者对于2.国务院，2019年。《一系列政策惠及2000万罕见病患者》网址：/xinwen第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT患者组织发挥的作用不仅仅是代表其成员利益。组织不仅为罕见病患者及其家庭提供教育资源，还促进有关诊断过跨国公司与中国⃞链接世界合作共赢和荣格纳标准6的病症，特别是那些早期治疗可显著改善预后的病筛查重点放在有家族史的高风险人群上，这样可以兼顾检测的成本和机器学习来识别模式、分析基因组和解读医学和诊断提供有力支持——例如通过检测个人电罕见病症状。对一些患者而言，若非借助这些第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT例如，Screen4Care8是由欧盟层面公共部门和私的项目，目标是加快罕见疾病诊断。该项目有两个重要方面包括在德国、捷克和意大利建立的两组罕见病新生儿基因筛查试点，第二个涉及利用数字工具进行更高效、更准确的医疗诊断，算法筛查出有罕见病风险的病人医疗档案、为病人提供自助症状，并准确推荐病人转诊接受专科治疗，将极大地改善治疗效果。例如，英格兰卫生教育部门根据其“基因组学教一个在线罕见病教育资源中心9，整合了罕见病患者的经验。该中心面向医疗保健专业人员，为他们可以采取的行们获取更多信息的途径。该中心由英格兰卫生教育部门与慈善机构），跨国公司与中国⃞链接世界合作共赢建议#3：整合医疗数据，助力研究、医疗的所在而四处奔波求医。在遵循地方、国家以及地区基础上，实现数据的汇集与共享，将有助于优化罕见例如，为了促进欧洲卫生系统的数字化转型，并在临床和研究目的上的共享，欧洲参考网络（ERN）建立了不同疾病的患者登记系统。例如，德国图宾根大学医院建立了ERN神经疾病（ERN-RND）登记系统11，参与ERN-RND的每位医疗专业人员都要提交一年中所有就诊患者的数据，利益相关者可申请访问这些数据，包括：临床医生和研究人员（ERN成员和非成员均可）；地区、国家和欧盟卫生政府部门；政策、监督和监管机构；患者组织和非政府组织。该网络的数据访问委员会负责提供相关数据——相关数据或ERN汇总数据，或是在申请人申请后由医务人员提供的病人匿名数据。利用这些数据，可以确定疾病和/或基因型特征，有助于临床研究的开展，也可为临床试验提供参考依据；同时也可了解到有多网址：https://www.ern-rn第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT诊疗网络有效融入医疗系统，以及确保不同地取网络内部的医疗资源。罕见病诊疗网络成功的其他关键因素还包括12：为网络内部的成员和机构提供教育和培训，促进临床研究、提供高质量医疗服务，向更广泛地传播专业知识，以及使得患者有例如，欧洲参考网络（ERNs）是欧洲在罕见病诊的典范，已成为欧洲以外其他罕见病网络学习的标ERNs是相关群体在欧盟层面广泛呼吁提高罕见病诊疗基于2009年欧洲理事会的一项建议文件14，这份文件建议欧盟各成员12.欧盟委员会，2023年。《欧洲参考网络持续监测和质量改进系统》，网址：https://health.ec.europa.eu/rare-dies-and-european-reference-networks/european-reference-networks/ern-continuous-monitoring-anence-networks/european-reference-n跨国公司与中国⃞链接世界合作共赢ERNs由欧洲委员会提供资金支持15，最新一轮资助金额覆盖2023-2027年，达到7740万欧元。其中，旨在将ERNs纳入国家卫生系统的JARDIN联合行动由欧盟资助1500万欧元，成员国资助375万欧元16。ERNs不仅能够在加能促进罕见病研究，例如通过对ERNs罕见神经疾病注册系统的有效利ERNs的另一个组成部分是临床患者管理系统(CPMS)17。该系统是一个电子健康数据共享平台，能够促进医生之间的跨国界他们更高效地开展多学科病例讨论，而无需患者亲自有17种可以全额报销，其余95种罕见病药物的住院报销比例通常在50%-70%之间，而门诊病人的报销比例ence-networks/eu4health-ticle/20240228/herald第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT且建立多样化医疗保障模式。在中国这样的多方支付基本医疗保险基金有限，政府也可以探索在国家医保原则1：罕见病药物需要通过特定的评估方法来评估其特殊的价例如，法国的“早期准入计划”19的资金来源主要是政府追回款项和法国医疗保险基金。可申请“早期准入”需治疗但缺乏合适替代疗法的疾病，包括罕见、严重或致残性疾病。现了国家为最需要的人提供创新医疗手段的基品可以申请适用该计划：一是已获得上市许可险报销范围的药品；二是尚未获批但承诺将申该计划下，研发者有责任从开具药品的医务人员和患者处收集数跨国公司与中国⃞链接世界合作共赢于孤儿药的价值评估系统应根据孤儿药的特殊性进行设计，而不照传统经济阈值，这是因为传统的经济阈值无法有效满足罕见病群体例如，在德国20，药品一经欧洲药品管理局(EMA)批在批准后的第一天向患者开具。在EMA对产品提供的“额外益处”做额在十二个月内超过3000万欧元的门槛时22，才会对药品进行全面的section/health-consumers/news/orphan-medicines-pharma-package-provisions-unleash-uncertaintieny-significantly-tightens-drug-pricing-and-reimbursement/docs/default-source/euro2024/evaluating-the-impact-of-benefit-reassessment-outcoorphan-drugs-surpassing-the-revenue-limit-in-germany146452-pdf.pdf?sfvrsn=47bc6713_0第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT格谈判。一项研究表明，重新评估益处之后，药价平均下降23.2%23。该项制度为患者和研发方提供了确定性，鼓励罕见病药物罕见病群体的费用负担，缓解医疗预算压力。随着创新科学转化为医），·以结果为导向的模式：该模式以在规定期限内取得特定临床结果为报销条件，由研发方和支付方共同承担风险。也就药品改善了医疗效果并降低了医疗成本，医疗系统会对此进行买单。西班牙的Kymriah和Yescarta（CAR-T细胞疗法）就采用患者在刚接受治疗时可以报销一部分治疗费，后期根据/wp-content/uploads/2022/03/eucope-ipm-pape跨国公司与中国⃞链接世界合作共赢在该模式下，若Luxturna疗法在实际中被证明了有效性，地区政府将·专项基金：一些国家为罕见病创新药物报销建立专项基金，如药物（包括许多罕见病药物）均拨款五亿欧元26，这两个基金在2021Yescarta在基于疗效的模式下由创新药物基金支付27。最近，《2025年预算法》28将该基金增加到每年12亿欧元，并重新关注创新药和罕·多层次支付：一些国家要求保险公司共同分担创新药物的经济负担。在德国，医疗费用超过10万欧元/年的患者，由国内所有医疗保险公司分担部分费用29。除公共保险外，商业机构也可以为罕见病患者提供支持，弥补公共报销对罕见病药物报销覆盖范围不足的问题。国家医疗保险部门应与商业保险公司建立综合/wp-content/uploads/2022/03/eucope-ipm-paper-202port/sites/MEF/focus/2024/documenti/article_00056/2025-/wp-content/uploads/2022/03/eucope-ipm-pape第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT的支出。为此，需要灵活设定病人适用的支付方式和卫生技术评估路径。设定自付上限非常重要，许多罕见病都遗传病，需要终身治疗，原则5：消除治疗可及性的地区性差异：罕见病治疗的地区差异依然存在，但国家层面可采取措施减少可及性在不同地区间的差异。在高昂的自付费用面前，即便病人预期特定药品有很强的临床疗效，也有可能不考虑用药。卫生部门应考虑根据家庭收入疗需求调整报销水平，以消除不同地区在药物可及性种调整要确保患者能够用上最理想的治疗剂量和经历例如，法国全国性长期病症（ALD）清单30上的药品的医疗费用由医疗系统100%报销。这些疾病包括严重的慢性病，涵盖部分罕见跨国公司与中国⃞链接世界合作共赢新适应症。我们将持续协同中国各地政府及合作伙伴，助力罕见病创新药可及，支持建设健全罕见病诊疗生态体系，共同助力实现“健康th第六届跨国公司领导人青岛峰会thTHESIXTHQINGDAOMULTINATIONALSSUMMITlatoryandpolicyframeworkforrarediseases.Thandsecondbatchesoftherespectively,whichcurrentlylishelpedtoimproveawarenessofrarediseasesamongthepublicandhealthprofessionalsinChina.Withthedesignationofspedevelopersofrelevantorphandrugsareaffordedvariouspreferentialpoli-ciesfrompriorityreviewtomarketingexclusivity.Thecountry’sNationalDrugReimbursementList(NDRL)–updatedonayearlybasissincediseasedrugsinrecentyears,reducthroughnationalmedicalinsurancefundwideorphandiseasetreatmentcollaborationnetworkandamanagementsystemhaslargelyreducedtimetodiagnosicommonchallenges:dispecialistsandcomprehensivecare,fewornoavailableth第六届跨国公司领导人青岛峰会thTHESIXTHQINGDAOMULTINATIONALSSUMMITmentalhealthchallenges,andfinancialandsocialimpacts.Mpeopleaspossiblewithlimitedresources.Thisreportproposesthefollowingpolicyrecommendationsbasedonpractices,aimingtoprovidevaluablereferencesforbuildingacomprehen-siverarediseaseecosystembringaboutthegreatestpossibdiseasesandforhealthcaresystems.Inpractice,thisdiagnosticpathwaysthatcanshortenthediagnosticotoprovidehigh-qualitycaretoeveryonelivingwitrainingforhealthcareprofessiona第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITWeshouldrecognizethecapableofeithercuringpatientsorsignificantlyreducinprogressive,debilitating,osystemfororphandrugsanddiversifypaymentmethods.Gifundingofthenationalbasicmedicalinsurancescheme,raisingbeyondthenationalbasicmedicalinsurancefundorestablishingrare跨国公司与中国⃞链接世界合作共赢PolicyAdvocacyReportditionworldwide.1China,forexample,hasapproximately20millioneachyear.2Thesefiguresreflectasignificantpartofthepopulation,alongsideincreasingrecognitionofrarediseasepriority.rarediseaseplansneedtocontaintneeds.Targetedpolicyapproachescangeneratetheoutcome.Thissectionexplorespragmaticapproacpolicymaking.Eachoftherecommendationswillalsoinclude“goodlocallevels.Recommendation#1:Includingpatientsinshareddecision-mak-1.TheLancet,2024.TheLandscapeforRareDiseasesin2024.[Online]Availableat:https://www.thelaPIIS2214-109X(24)00056-1/fulltext#:~:text=By%20definition%2C%20rare%20diseases%20affect,people%20live%20with%20rare2.StateCouncil,2019.ASeriesofPoliciesBenefit20MillionRareDiseasePatients.[Online]Availableat:https://w2019-03/02/content_5369882第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMIT“Patientcentricity”isanoft-citedterminhealthcarepolicy,asamodelofinclusivityandparticipation.Ppaperasbeigatthecenterofdecision-making,whileinpracticethesystemssetuptocollectinformationontheirviewsandprioritieoften,decisionsaremadeaboutpatientsratherthanwiththem.apassiveentitytorecognizingtheiractiveroleas“expertsbyexpeorganizationsthatrepresentthem,hgovernments,andpolicymakers–playingaleadingroleinthehavetheirviewsnotonlyheardbutacteduponbytheirgovernment跨国公司与中国⃞链接世界合作共赢diagnosticodyssey,treatmentoptionsandresources,tionsalsoservetoconnectthemedicalcommunitywiththeperspec-tivesandneedsofpeoplelivingwiththeconditionstheytreat.withtheircounterpartsinothercountries.Thereisaneedtrainingtoleadersinrarediseasecommunities,giventheirimportantrolesinthedevelopmentofpatnessaboutrarediseas3.EURORDISOpenAcademy,2024.OpenAcademySchools2025.[Online]Availableat:/open-acade-4.EURORDISOpenAcademy,2024.Alumni.[Online]Availableat:https://openacademy.eurord5.EURORDISOpenAcademy,2024.AllCourses.[Online]Availableat:https://openacademy.eurord第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITRecommendation#2:OptimizingandimprovingearlydiaToensurethebestpossibleoutodyssey,itisvitaltoenhancemedicaleducatioaroundrarediseases.Improvedaccesstoraredisease-relatedtrainingforhealthcareprofessionals,includingwithinuniversities,iscrucial.Thismustbeaccompaniedbyinvestmentininitiativessuchasnew-bornscreening,patientartificialintelligenceapplications.TheconditionschosenforinclusioninneJungner6criteria–parcantlyimproveoutcomes,andwhetherthetestsarereliableacost-effective.However,thesecriteria(anddifferencesinhowcoun-mind.7Onesuggestionformanagingthecost-effectivenessofnew-6.Wilson,JamesMaxwellGlover,Jungner,GunnarCWorldHealthOrganization.(1968).PrinciplesandpracticeofscreeninWorldHealthOrganization./handle/10665/377.Schnabel-BessonE,MützeU,DikowN,HörsterF,MorathMA,AlexK,BrennenstuhlH,SettegastS,OkunJG,SchaafCP,WinklerEC,KölkerS.WilsonandJungnerRevisited:AreScreeningCriteriaFitforthe21stCentury?IntJNeonatalScreen.2024Sep13;10(3):62.doi:10.3390/ijns10030062.PMID:39311364;PMCID:P跨国公司与中国⃞链接世界合作共赢bornscreeningcouldbeAlso,ArtificialIntelligence(AI)isrevolutionizingrarediseasediagnosticsinseveralways.Theuseofdataandmachinelearningtoichealthrecordstodetectpatternsthatmightbereflectiveofrarediseases,includinginpeoplewhomayEU-levelpublic-privatepartnershiofgeneticnewbornscreeninginGermany,Czechia,andItalyfortwosetsofrarediseases.Thesecondprrecommendations,andavirtualclinipatientstotherightspecialistcarecanmakeahucomes.Integratingrarediseaseandgeneticsineducationan8.Screen4Care,2024.WhatisScreen4Care?[Online]Availableat:https://screen4ca第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITcurriculaisimportantfortheimprovementandmedicalservicesprovisiontintegratingtheexperiencesoftheycantakeandlettingthemknowwheretheycanlRecommendation#3:Poolingandharmonizationofdataforresearch,diagnosis,andhealthtechnologyInanidealworld,knowlandmedicalinstitutions,aswellaspotentiallywithpartnercountriesimprovementsincareandresearch,aswellasacollectio9.HealthEducationEngland(HEE),2022.Rarediseaseeducationhub.[Online]Availableat:https://www.genomicraredisease-education-hu10Medics4RareDiseases,2024.TheHistoryofM4RD.[Online]Availableat:https://www.跨国公司与中国⃞链接世界合作共赢real-worlddatathatcouldinformhealthtechnologyassessmenForexample,theERNscreatepatientregistries,withaviewtopromotingthedigitaltransformationofEuropeanhealthsystemsandple,theERNonNeurologicalDiseases(ERN-RND)registry11establishedatUniversityHospitalTübingen,Germany.EveryhecareprofessionalinvolvedintheERN-RNDsubmitsdatothisdata:cliniciansandresearchers(ERNbers),regional,national,andEUhethedata–providingaggregateddatadirectlyfromthrequestingpseudonymizecareprofessional.Usidiseaseand/orgenotype-specificcohortsfinformclinicaltrials–aslecularlyconfirmeddiagnosis,furtherunderlyingtheondiagnostics.11.ERNNeurologicalDiseases(ERN-RND),2024.ERN-RNDRegistry.[Online]Availableat:https://www第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITRarediseasecollaborativenetworksarebestpracticemodelsforlinkingpatientstomultidilessoftheirlocation.Regionalandnationalgovernmentswillneedtocommittointe-accessibility,ifthecessfulrarediseasecarenetworksinclude:12provisionofeducationhigh-qualityhealthcareservices,disseminationoftheirthewidercommunity,andpositivepatientexperiencewerearesultofextensiveadvocacyforactiononraredis12.EuropeanCommission,2023.ERNContinuousMonitoringandQualityImprovementSeuropa.eu/rare-diseases-and-european-reference-networks/european-reference-networks/erncontinuous-monitoring-and-qu13.EuropeanCommission,2024.EuropeanReferenceNetworks.[Online]Availableat:https://health.ec.europa.eu/rare-diseases-and-eu-ropean-reference-networks/european-reference-networks_跨国公司与中国⃞链接世界合作共赢theEUlevel,buildingonaCouncilRecommendawhichtheMemberStatesagreedtoidentifycentresnationallyandsupporttheirparticipationinEuropeannetworklatest77.4millionEURgrantcovering2023-2027,andtheJARDIN15millionEURofEUfundingand3.75millionEURfromtrarediseaseresearchinnewtherapecarepathways–forexample,throughtheERN-RNDregistry.1614.EUR-Lex,2009.CouncilRecommendationof8June2009onanactioninthefieldofrarediseases.[Online]Availableat:https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32009H0703(015.EuropeanCommission,2024.EU4Healthfunding.[Online]Availableat:https://health.ec.europa.eu/rare-diseases-and-european-refer-ence-networks/eu4health-fund16.ERNNeurologicalDiseases(ERN-RND),2024.ERN-RNDRegistry.[Online]Availableat:https://www.17.ERNNeurologicalDiseases(ERN-RND),2024.OnlinecasediscussionwithCPMS.[Online]Availableat:https://www.ern-rnd.eu-/cpms/第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITAccesstorarediseasetreatmentsisfunding.Patientsfacehighout-of-pocketcostsastrdiseasedrugsthatarenotfullyreimbursabletypicallyrangebetween50%-70%,whileoutpatientratestendtobelower.18Differingleofeconomicdevelopmentindifferentptorsindeterminingtherelbear.multi-playermarkets,suchasfundscanpotentiallyhelpreducetherarediseasefundinggGuidingprinciplesforrarediseasedruPrinciple1:Rarediseasemedicinesrequiretailoredassessmeurgentneedforavalueassessmentsystemwhichgo18.21stCenturyBusinessHerald,2024.GovernmentFocusesonIncreasingMedicalSecurityforRareDiseasePatients.[Online]Avail-ableat:/article/20240228/herald/6128373a62324baa586bf5394a6c32b跨国公司与中国⃞链接世界合作共赢dardmethodsofdeterminingtaccountpharmacoeconomics,medicalinnovation,andtheurgencyofPrinciple2:Pricingandreimbursementshouldbebasedontvalueassessmentsystem,orphanmedicinalproducts(OMPs),ratherthanonconventionale19.HauteAutoritédesanté(HAS),2023.Accèsprécoceàunmedicament.[Online]Availableat:https://www.has-sante.fr/-jcms/r_1500918/fr/acces-precoce-a-un-medicament第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITnomicthresholdswhichcrarediseasecommunityforinnovativetreatmenttheEuropeanMedicinesAgency(EMA),itcanpatientsonDayOnepost-approval.MedicinetionalbenefittheproductprovideassignedbyanArbitrationBoard.However,products21thathavebeengrantedtheorphandesigna-additionalbenefit(significantbenefitoverexistingtreatmenensuresthattheyreceiveaposassessmentonlytakesplaceifthemedicine’ssalescrossathreshold20.TheCommonwealthFund,2019.HowDrugPricesAreNegotiatedinGermany.[Online]Availableat:monwealth-/blog/2019/how-drug-prices-are-negotiated-21.Euractiv,2024.OrphanmedicinesPharmapackageprovisionsunleashuncertainties,stakeholderswarn.[Online]Availableat:/section/health-consumers/news/orphan-medicines-pharma-package-provisions-unleash-uncertainties-stake-跨国公司与中国⃞链接世界合作共赢of30millionEURwithintheprevioustwelvemonths,22whichleadstopricerenegotiationsfollowinganupdatedbenefitassessment.Onefurtherorphanmedicinesandmavailableinpractice.Principle3:Exploreinnovativepaymeninalproductsthatmaystrchallengesindataavailability,lackofeconomiesofscaleincomplex22.Covington,2022.GermanysignificantlytightensDrugPricingandReimbursementLaws.[/2022/10/26/germany-significantly-tightens-drug-pricing-and-reimbursement-laws/23.Roberts,G.etal.,2022.EvaluatingtheimpactofbenefitreassessmentoutcomesfororphandrugssurpassingtherevenuelimitinGermany.ISPOREuropePresentation[Onli/docs/default-source/euro2024/evaluating-the-impact-of-benefit-reassessment-outcomes-for-orphan-drugs-surpass-ing-the-revenue-limit-in-germany146452-pdf.pdf?sfvrsn=47bc67第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITbioproductionprocesses,andmeetingaffordabtionofadditionalfinancing(outsidethenationalinsurancefund)andcreativepaymentmethodsshouldbeexploredtoaddressthesebarrierstorisk-sharingbetweendevelopersandpayers–andessentiallymeaningthatthehealthsystemispayingforimprovedhealthoutcotheybringthroughreducedhealthcarecosts.ThismodforKymriahandYescarta(CAR-Tcelltherapies),involvingpartialreim-bursementatthetimeofdeliveryandafurtherpaymentdepeoutcomeforeachtreatmentrecipient.24•Annuitypayments:Suchoutcome-basedmodbinedwithspreadingoutreimbursementpaymentsoveraperiodofyears.ThesepaymentplansprovidehealthcsionforLuxturna(agenetherapyforararedisease)24.EUCOPEWorkingGrouponGeneCCellTherapies,2021.AdvancedTherapiesMedicinalProducts:newpaymentandfundingapproaches.[Online]Availableat:/wp-content/uploads/2022/03/eucope-ipm-paper-2021.跨国公司与中国⃞链接世界合作共赢wouldpayforthetreatmentininstallmentsifitdemonstrateditseffective-specificfundsforinnovativerarediseconsisted26of500millionEUR/yearforcancermedicines,andEUR/yearfornon-cancermedicannuallyandrefocusesonbothinnovativeandorphanmedicine•Multi-layeredfunding:Finally,somecountriesrequireinsuresharetheburdenofprovidingaccesstoinnovativemedicinefundingrulespartiallysharethecostsofsupportingpatientswhosecare26.PMU80TheItalianInnovationAcceleration?BestPracticeLessonsofReimbursementIncentivesforInnovativeProductsMacaulay,R.etal.ValueinHealth,Volume23,S247[Online]Availableat:/articl/fulltext27.UCOPEWorkingGrouponGeneCCellTherapies,2021.AdvancedTherapiesMedicinalProducts:newpaymentandfundingapproaches.[Online]Availableat:/wp-content/uploads/2022/03/eucope-ipm-paper-2021.p28.Ministerodell’EconomiaedelleFinanze(MEF),2024.BilanciodiprevisionedelloStatoperl'annofinanzinaleperiltriennio2025-2027.[Online]Availableat:.it/export/sites/MEF/focus/2024/documenti/articlDLB-Relazione-Articolato-e-Quadri-Generali.pdf第六届跨国公司领导人青岛峰会THESIXTHQINGDAOMULTINATIONALSSUMMITcostsexceed100,000EUR/Beyondpublicinsurance,thereisaroleforcommercialproviderstooffrarediseasepatientssupportthatfillsthegapcoverage.Thenationalhealthcareinsurancedepartmengratedsettlementaccountswithcomoninternationalprivateinsuranceexperienpatientshaveaffordableout-of-pocketpaymentshelpskeepcostsdownforbothpeoplelivingwith